Topological role of cytochrome P450 2D6 active site residues

被引:9
|
作者
van Waterschoot, RAB
Keizers, PHJ
de Graaf, C
Vermeulen, NPE
Tschirret-Guth, RA [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA
[2] Vrije Univ Amsterdam, LACDR, Div Mol Toxicol, Dept Pharmacochem, NL-1081 HV Amsterdam, Netherlands
关键词
cytochrome p450 2D6; active site topology; aryldiazenes; mutagenesis; molecular modeling;
D O I
10.1016/j.abb.2006.01.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent reports have identified Phe120, Asp301, Thr309, and Glu216 as important residues in cytochrome P450 2D6 (CYP2D6) substrate binding and catalysis. Complementary homology models have located these amino acids within the binding pocket of CYP2D6 and in the present study we have used aryldiazenes to test these models and gain further insight in the role these amino acids have in maintaining the integrity of the active site cavity. When Phe120 was replaced to alanine, there was a significant increase in probe migration to pyrrole nitrogens C and D, in agreement with homology models which have located the phenyl side-chain of Phe120 above these two pyrrole rings. No changes in topology were observed with the D301Q mutant, supporting claims that in this mutant the electrostatic interactions with the B/C-loop are largely maintained and the loop retains its native orientation. The T309V Mutation resulted in significant topological alteration suggesting that, in addition to its potential role in dioxygen activation, Thr309 plays an important structural role within the active site crevice. Replacement of Ile106 with Glu, engineered to cause electrostatic repulsion with Glu216, had a profound topological effect in the higher region within the active site cavity and impaired the catalytic activity towards CYP2D6 probe substrates. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:53 / 58
页数:6
相关论文
共 50 条
  • [41] Inhibition of human cytochrome P450 2D6 by schering 66712
    Butler, Brendan Francis
    Palamanda, Jairam
    Nomeir, Amin A.
    Guengerich, F. Peter
    Furge, Laura Lowe
    FASEB JOURNAL, 2007, 21 (05): : A670 - A670
  • [42] Inhibitory monoclonal antibodies to human cytochrome P450 2D6
    Krausz, KW
    Yang, TJ
    Gonzalez, FJ
    Shou, MG
    Gelboin, HV
    BIOCHEMICAL PHARMACOLOGY, 1997, 54 (01) : 15 - 17
  • [43] Tardive dyskinesia and cytochrome P450 2D6 genotyping in schizophrenia
    Lam, LCW
    Ungvari, GS
    Garcia, M
    Kwong, SL
    Chiu, HFK
    SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 261 - 261
  • [44] PERSONALIZED PHARMACOTHERAPY IN A PATIENT WITH CYTOCHROME P450 2D6 POLYMORPHISM
    Paul, Sheeba
    Lu, Celia
    Block, Lauren
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S561 - S562
  • [45] Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis
    Guengerich, FP
    Hanna, IH
    Martin, MV
    Gillam, EMJ
    BIOCHEMISTRY, 2003, 42 (05) : 1245 - 1253
  • [46] Cytochrome P450 2D6 GenotypingPotential Role in Improving Treatment Outcomes in Psychiatric Disorders
    Julia Kirchheiner
    Cristina Rodriguez-Antona
    CNS Drugs, 2009, 23 : 181 - 191
  • [47] Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4 and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A in vitro
    Paludetto, Marie-Noeurolle
    Kurkela, Mika
    Kahma, Helina
    Backman, Janne T.
    Niemi, Mikko
    Filppula, Anne M.
    DRUG METABOLISM AND DISPOSITION, 2023, 51 (03) : 293 - 305
  • [48] Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate
    McConnachie, L
    Bodor, M
    Kowdley, K
    Levy, A
    Tung, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DA
    Ho, RJY
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (04) : 282 - 297
  • [49] Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6
    de Graaf, Chris
    Oostenbrink, Chris
    Keizers, Peter H. J.
    van Vugt-Lussenburg, Barbara M. A.
    van Waterschoot, Robert A. B.
    Tschirret-Guth, Richard A.
    Commandeur, Jan N. M.
    Vermeulen, Nico P. E.
    CURRENT DRUG METABOLISM, 2007, 8 (01) : 59 - 77
  • [50] Effect of Lipid Bilayer Anchoring on the Conformational Properties of the Cytochrome P450 2D6 Binding Site
    Guvench, Olgun
    JOURNAL OF PHYSICAL CHEMISTRY B, 2024, 128 (29): : 7188 - 7198